A possible role of the ATP-sensitive potassium ion channel in determining the duration of spike-bursts in mouse pancreatic beta-cells.
The pancreatic beta-cell displays an electrical activity consisting of spike bursts and silent phases at glucose concentrations of about 10 mM. The mechanism of initial depolarization induced by glucose is well defined. However, the mechanism inducing the silent phase has not been fully elucidated. In the present study, the possibility of involvement of ATP-sensitive K+ channels in repolarization was examined using the patch-clamp technique in the cell-attached recording configuration. Ouabain (0.1 mM), an inhibitor of Na+/K+-ATPase, caused a complete suppression of ATP-sensitive K+ channel activity followed by typical biphasic current deflections, which were due to action potentials. The channel activity was also inhibited by removal of K+ from a perifusion solution. Furthermore, the activity of ATP-sensitive K+ channels was markedly inhibited either by replacement of external NaCl with LiCl or by addition of amiloride (0.2 mM), a blocker of Na+/H+ antiport. Addition of L-type Ca2+ channel blockers such as Nifedipine for Mn2+ induced the complete suppression of K+ channel activity. These findings strongly suggest that a fall in ATP consumption results in sustained depolarization, and that the repolarizations interposed between spike-bursts under normal ionic conditions are due to the periodical fall of ATP concentration brought about by periodical acceleration of ATP consumption at Na+/K+-pumps. It is concluded that the elevation of intracellular Na+ concentration as a consequence of accelerated Na+/Ca2+-countertransport during the period of spike-burst enhances ATP consumption, leading to a fall in ATP concentration which is responsible for termination of spike-burst and initiation of repolarization.
Ding
W G
WG
Department of Physiology, Shiga University of Medical Science, Ohtsu, Japan.
He
L P
LP
Omatsu-Kanbe
M
M
Kitasato
H
H
D000200:Action Potentials; D000255:Adenosine Triphosphate / Q000378:metabolism*; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007515:Islets of Langerhans / Q000502:physiology*; D008297:Male; D008345:Manganese / Q000494:pharmacology; D051379:Mice; D008813:Mice, Inbred ICR; D009543:Nifedipine / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000378:metabolism / Q000502:physiology; D015221:Potassium Channels / Q000502:physiology*; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors
D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D015221:Potassium Channels; D008345:Manganese; D010042:Ouabain; D000584:Amiloride; D000255:Adenosine Triphosphate; D000254:Sodium-Potassium-Exchanging ATPase; D009543:Nifedipine; D011188:Potassium